Related Experiment Video
Updated: May 13, 2025

Digital Home-Monitoring of Patients after Kidney Transplantation: The MACCS Platform
Published on: April 12, 2021
Patient portal messaging to address delayed follow-up for uncontrolled diabetes: a pragmatic, randomised clinical
Arielle R Nagler1, Leora Idit Horwitz2, Aamina Ahmed2
1The Ronald O Perelman Department of Dermatology, NYU Grossman School of Medicine, New York, New York, USA arielle.nagler@nyulangone.org.
Importance:
Patients with poor glycaemic control have a high risk for major cardiovascular events. Improving glycaemic monitoring in patients with diabetes can improve morbidity and mortality.
Objective:
To assess the effectiveness of a patient portal message in prompting patients with poorly controlled diabetes without a recent glycated haemoglobin (HbA1c) result to have their HbA1c repeated.
Design:
A pragmatic, randomised clinical trial.
Setting:
A large academic health system consisting of over 350 ambulatory practices.
Participants:
Patients who had an HbA1c greater than 10% who had not had a repeat HbA1c in the prior 6 months.
Exposures:
A single electronic health record (EHR)-based patient portal message to prompt patients to have a repeat HbA1c test versus usual care.
Main Outcomes:
The primary outcome was a follow-up HbA1c test result within 90 days of randomisation.
Results:
The study included 2573 patients with a mean (SD) HbA1c of 11.2%. Among 1317 patients in the intervention group, 24.2% had follow-up HbA1c tests completed within 90 days, versus 21.1% of 1256 patients in the control group (p=0.07). Patients in the intervention group were more likely to log into the patient portal within 60 days as compared with the control group (61.2% vs 52.3%, p<0.001).
Conclusions:
Among patients with poorly controlled diabetes and no recent HbA1c result, a brief patient portal message did not significantly increase follow-up testing but did increase patient engagement with the patient portal. Automated patient messages could be considered as a part of multipronged efforts to involve patients in their diabetes care.
Related Concept Videos
Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Diabetes Mellitus: Type 2 and Gestational
Feedback Loops
Chronic Pancreatitis II: Collaborative Care
Assessment:
Diabetes Mellitus: Overview and Type I Subtype
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Insulin: Dosing Regimen and Adverse Effects
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...

